Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma
Mantle cell lymphoma accounts for 4-6% of B-cell non-Hodgkin lymphoma (NHL) with historically poor outcomes. With the advent of intensive first-line, targeted, and cellular therapies, outcomes have improved, and initial remission can be 8-10 years or even longer. As patients experience longer remissions, this raises the question of the optimal surveillance modality. Peripheral blood minimal residual disease (MRD) analysis offers a potential alternative to surveillance imaging that sensitive, less costly, and eliminates the risk of radiation exposure.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Alexandra Rezazadeh, Julie Pruett, Amy Detzner, Natasha Edwin, Mehdi Hamadani, Nirav N. Shah, Timothy S. Fenske Tags: Original Study Source Type: research
More News: Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Study